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Abstract
Background: Strong evidence exists that substance use is a contributory risk factor for intimate partner abuse (IPA)
perpetration. Men in substance use treatment are more likely to perpetrate IPA than men from the general
population. Despite this, referral pathways are lacking for this group. This trial will assess the feasibility of
conducting an evaluation trial of a tailored integrated intervention to address substance use and IPA perpetration
to men in substance use treatment.
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Methods/design: ADVANCE is a multicentre, parallel-group individually randomised controlled feasibility trial, with
a nested formative evaluation, comparing an integrated intervention to reduce IPA + substance use treatment as
usual (TAU) to TAU only. One hundred and eight men who have perpetrated IPA in the past 12 months from
community substance use treatment in London, the West Midlands, and the South West will be recruited.
ADVANCE is a manualised intervention comprising 2–4 individual sessions (2 compulsory) with a keyworker to set
goals, develop a personal safety plan and increase motivation and readiness, followed by a 12-session weekly group
intervention delivered in substance use services. Men will be randomly allocated (ratio 1:1) to receive the ADVANCE
intervention + TAU or TAU only. Men’s female (ex) partners will be invited to provide outcome data and offered
support from integrated safety services (ISS). Regular case management meetings between substance use and ISS
will manage risk. Outcome measures will be obtained at the end of the intervention (approximately 4 months post-
randomisation) for all male and female participants. The main objective of this feasibility trial is to estimate
parameters required for planning a definitive trial including rates of consent, recruitment, and follow-up by site and
group allocation. Nested formative evaluation including focus groups and in-depth interviews will explore the
intervention’s acceptability to participants, group facilitators, keyworkers and ISS workers. Secondary outcomes
include substance use, IPA, mental health, self-management, health and social care service use, criminal justice
contacts, and quality of life.
Discussion: Findings from this feasibility trial will inform the design of a multicentre randomised controlled trial
evaluating the efficacy and cost-effectiveness of the ADVANCE intervention for reducing IPA and improving the
well-being of female (ex)partners.
Trial registration: ISRCTN79435190.
Background
Intimate partner abuse (IPA) includes any incident/pat-
tern of incidents of controlling, coercive or threatening
behaviour, violence, or abuse between current or former
partners [1]. Women are more likely to experience sex-
ual violence, injury, or be murdered by a partner than
men [2–5]. While no single factor explains why some
people perpetrate IPA [6, 7], there is strong and consist-
ent evidence that substances, particularly alcohol,
cocaine, and methamphetamines are contributory risk
factors for IPA perpetration [8–16]. This association is
significantly stronger from men who abuse or are
dependent on alcohol or drugs [16]. The complex inter-
play between substance use and IPA perpetration
includes intoxication (change or disinhibition when
under the influence of alcohol or stimulant drugs), with-
drawal and craving (irritability and frustration or the
need to acquire substances), the impact of substance use
on relationships, the wider dynamics of power and con-
trol, and psychological vulnerabilities (adverse childhood
experiences, mental health, and emotional instability)
linked to substance use and IPA [17, 18]. At least 3 in
10 men receiving substance use treatment have been
physically or sexually violent, and 7 in 10 men have been
psychologically abusive towards their partner in the pre-
vious year [3, 8, 9, 19–21]. These rates are far higher
than amongst the general population [12, 14]. Around
three-quarters of men attending substance use treatment
in England had ever perpetrated any IPA towards their
partner [9].
Despite the association between IPA perpetration and
substance use, and the higher prevalence of IPA perpet-
ration amongst men receiving substance use treatment,
there is a lack of care pathways including perpetrator
programmes for this client group [22]. Community per-
petrator programmes in England (UK) meet only 10% of
the existing demand [23]. Men who use substances are
rarely referred to perpetrator programmes and when they
are, treatment completion is low and attendance/uptake
poor [24–27]. In one US study, only 17% of 658 men seek-
ing alcohol treatment who had perpetrated IPA in the past
year were referred to a perpetrator programme by the
alcohol treatment service, and only 15 (13%) enrolled in
the programme [27]. Amongst 286 males convicted for in-
timate partner violence and court-mandated to attend a
community-perpetrator programme in Spain, a significantly
higher rate of intervention drop-out was reported amongst
men with alcohol problems (36% vs. 23%, p < .05) [26].
Few perpetrator interventions have been trialled
amongst men who use substances [28]. A recent review
of interventions to reduce IPA perpetration by men who
use substances identified only nine trials, three of which
were conducted in substance use treatment services
and two of these amongst men who had been arrested
for IPA or court-mandated to receive the intervention
[28]. Initial reviews of IPA interventions conducted
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concurrently with alcohol treatment [29] or integrated
interventions that address both IPA and substance use
[28] show some promise but were not superior to treat-
ment as usual [28]. Some interventions to address IPA
in men who use substances present a simplistic model of
inebriated physical violence and struggle to integrate
issues of gender, non-physical abuse and to fully con-
sider the impact of a substance use lifestyle. Recent
research has identified that it is not one factor that ex-
plains causal pathways into IPA, but rather a multilevel
and multifactor explanation is required [17, 18, 30]. A
nested ecological model identifies factors at 4 levels,
including structural factors such as patriarchy, sub-
cultural factors, for example, high tolerance for general
alcohol use, familial factors, including modelling from
family of origin and social learning theory, and individ-
ual factors such as high anger or high impulsivity [31].
This multifactorial response requires a more nuanced
understanding of the roles of substance use in IPA per-
petration that is wider than intoxicated abuse. With-
drawal and craving present as many risks as intoxication
and intensify coercive control [18]. Many perpetrators
report psychological problems and explain IPA as a
shared response to anxiety or depression and anger,
often from emotional insecurities shaped by negative
childhood experiences, and mediated by substances [17].
Rationale
IPA is not routinely identified or addressed in substance
use treatment, resulting in a large proportion of perpe-
trators who might benefit from treatment being missed.
Ultimately, training substance use treatment staff to
deliver integrated interventions to address IPA in sub-
stance use treatment services would increase their reach.
We are not aware of any UK-based randomised con-
trol trials of the effectiveness of perpetrator programmes
for men who use substances. Further research is needed
to develop and test integrated interventions that address
IPA and substance use concurrently. The provision of
strategies to holistically address both may be more
effective [32].
Methods
The protocol (Version 5, 13 November 2018) complies
with the guidelines of the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
[33] (Table 1).
Aim
This trial will assess the feasibility of conducting an
evaluation trial of an integrated intervention to address
both substance use and IPA perpetration to men in
substance use treatment.
Design
A multicentre, parallel group, individually randomised
controlled feasibility trial with a nested formative evalu-
ation, comparing an integrated intervention to reduce
IPA + usual substance use treatment, to usual substance
use treatment only for men in substance use treatment.
Setting and participants
One hundred and eight male participants will be re-
cruited from NHS and voluntary organisation community
substance use treatment services in three regions in Eng-
land (two services in London, two services in the West
Midlands and two services in the South West). Sets of up
to 18 men per treatment service will be randomised. Three
sets of the 16-week ADVANCE intervention, one in each
region, will be completed (cycle 1) and a formative evalu-
ation undertaken to inform the implementation of cycle 2
(a further three sets of the intervention, one in each
region). Up to 18 men per set will randomised per cycle.
The female current or former partners of men recruited
to the trial will be offered support from an integrated safety
service and invited to provide outcome data for the trial.
Based on recruitment figures from other evaluations of per-
petrator programs [34] and a recent UK-based perpetrator
intervention [35], it is estimated that up to 70% of their
current or former female partners will be recruited (n = 76).
Inclusion and exclusion criteria
Men attending the substance use treatment services are
eligible if:
1. They have perpetrated IPA towards a current or ex
female partner in the last 12 months
2. Have had face-to-face/phone/text/social media
contact at least once with that partner in the last 12
months
3. Plan to stay in the current location for the next 6
months
4. Agree to provide contact details of current and/or
ex female partner
5. Able to understand and communicate in English
Men will be excluded if any of the following apply:
1. Current restraining orders prohibiting them or
anyone on their behalf (e.g. the women’s support
worker or the researcher) from contacting their
current or ex female partner
2. Pending court cases for IPA as it is uncertain how
they will be sentenced (i.e. they may not be able to
participate in the trial)
3. Pending child protection hearings to ensure that
participating in the trial could not be used to
influence proceedings
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Table 1 SPIRIT Checklist
Section/item Item
no.
Description Addressed on
page number
Administrative information
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial
acronym
Title page
Trial registration 2a Trial identifier and registry name. If not yet registered, name of the intended registry Abstract, 2
Protocol version 3 Date and version identifier 3
Funding 4 Sources and types of financial, material, and other support 15
Roles and responsibilities 5a Names, affiliations, and roles of protocol contributors 15
5b Name and contact information for the trial sponsor 15
5c Role of study sponsor and funders, if any, in study design; collection, management, analysis,
and interpretation of data; writing of the report; and the decision to submit the report for
publication, including whether they will have ultimate authority over any of these activities
15
5d Composition, roles, and responsibilities of the coordinating centre, steering committee,
endpoint adjudication committee, data management team, and other individuals or groups
overseeing the trial, if applicable (see Item 21a for data monitoring committee)
14
Introduction
Background and
rationale
6a Description of research question and justification for undertaking the trial, including summary
of relevant studies (published and unpublished) examining benefits and harms for each
intervention
2–3
6b Explanation for choice of comparators 10
Objectives 7 Specific objectives or hypotheses 3, 10–11
Trial design 8 Description of trial design including type of trial (e.g. parallel group, crossover, factorial, single
group), allocation ratio, and framework (e.g. superiority, equivalence, noninferiority, exploratory)
3
Methods: participants, interventions, and outcomes
Study setting 9 Description of study settings (e.g. community clinic, academic hospital) and list of countries
where data will be collected. Reference to where list of study sites can be obtained
3
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres
and individuals who will perform the interventions (e.g. surgeons, psychotherapists)
3, 6
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when
they will be administered
9–10
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (e.g.
drug dose change in response to harms, participant request, or improving/worsening disease)
13
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring
adherence (e.g. drug tablet return, laboratory tests)
10
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 10
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (e.g.
systolic blood pressure), analysis metric (e.g. change from baseline, final value, time to event),
method of aggregation (e.g. median, proportion), and time point for each outcome.
Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly
recommended
11–13
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments,
and visits for participants. A schematic diagram is highly recommended (see figure)
Fig. 1, Table 2, 6–8
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was
determined, including clinical and statistical assumptions supporting any sample size
calculations
13–14
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 10
Methods: assignment of interventions (for controlled trials)
Allocation:
Sequence generation 16a Method of generating the allocation sequence (e.g. computer-generated random numbers),
and list of any factors for stratification. To reduce predictability of a random sequence, details
of any planned restriction (e.g. blocking) should be provided in a separate document that is un-
available to those who enrol participants or assign interventions
8
Allocation 16b Mechanism of implementing the allocation sequence (e.g. central telephone; sequentially 8
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4. Attending an intervention for IPA perpetration
For eligible men following the screening, the keywor-
ker at the substance use treatment service will assess
men’s suitability to participate in the trial.
For women whose current or former partners are
participating in the trial, inclusion criteria include
1) Being aged 18 years or older
2) An ability to understand and communicate in English
Table 1 SPIRIT Checklist (Continued)
Section/item Item
no.
Description Addressed on
page number
concealment
mechanism
numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until
interventions are assigned
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign
participants to interventions
8
Blinding (masking) 17a Who will be blinded after assignment to interventions (e.g. trial participants, care providers,
outcome assessors, data analysts), and how
8
17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a
participant’s allocated intervention during the trial
8
Methods: data collection, management, and analysis
Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any
related processes to promote data quality (e.g. duplicate measurements, training of assessors)
and a description of study instruments (e.g. questionnaires, laboratory tests) along with their
reliability and validity, if known. Reference to where data collection forms can be found, if not
in the protocol
11–13
18b Plans to promote participant retention and complete follow-up, including a list of any outcome
data to be collected for participants who discontinue or deviate from intervention protocols
10
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote
data quality (e.g. double data entry; range checks for data values). Reference to where details of
data management procedures can be found, if not in the protocol
11–13
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other
details of the statistical analysis plan can be found, if not in the protocol
14
20b Methods for any additional analyses (e.g. subgroup and adjusted analyses) 14
20c Definition of analysis population relating to protocol non-adherence (e.g. as randomised ana-
lysis), and any statistical methods to handle missing data (e.g. multiple imputation)
14
Methods: monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure;
statement of whether it is independent from the sponsor and competing interests; and
reference to where further details about its charter can be found, if not in the protocol.
Alternatively, an explanation of why a DMC is not needed
13–14
21b Description of any interim analyses and stopping guidelines, including who will have access to
these interim results and make the final decision to terminate the trial
13
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported
adverse events and other unintended effects of trial interventions or trial conduct
13
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be
independent from investigators and the sponsor
13
Ethics and dissemination
Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 15
Protocol amendments 25 Plans for communicating important protocol modifications (e.g. changes to eligibility criteria,
outcomes, analyses) to relevant parties (e.g. investigators, REC/IRBs, trial participants, trial
registries, journals, regulators)
15
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised
surrogates, and how (see Item 32)
6-8
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared,
and maintained in order to protect confidentiality before, during, and after the trial
14
Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each
study site
15
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Women will be excluded if any of the following apply:
1) Pending court cases for IPA
2) Pending child protection hearings
In exceptional circumstances, clinicians can override
the inclusion criteria to ensure that female current or
former partners are safeguarded including (1) where the
female and male participant share a mobile phone and
(2) where the female partner lives outside the UK and
therefore integrated safety support cannot be provided—
neither will be eligible to take part in the feasibility trial.
Male current or former partners and non-English
speaking female current or former partners of men in
the trial will not be invited to provide outcome data but
will be offered support for their IPA victimisation.
Recruitment
Participation in the trial requires a two-stage informed
consent process. Firstly, men must consent to be screened
for eligibility. If eligible after screening, men then consent
to take part in the trial. Researchers will screen potential
male participants for eligibility using the Revised Abusive
Behavior Inventory [36]. Men already attending substance
use treatment will be identified in substance use treatment
waiting rooms, via keyworkers or will contact researchers
from details on flyers/posters advertising the research (Fig.
1). Researchers will also attend support groups delivered
in the substance use service to explain the study and invite
interested men to discuss the study further. Men who re-
port this is their first appointment at the service will not
be screened as they may not be enrolled in the service fol-
lowing assessment. To be eligible to participate in the trial,
male participants have to be receiving treatment from the
participating substance use service.
Researchers will explain the study to interested men,
provide them with an information sheet and gain in-
formed consent to undertake the screening, including lim-
itations to confidentiality and consent to discuss the
screening and their suitability to take part in the trial with
their keyworker. Consent forms will be counter-signed in
triplicate by both the male participant and the researcher.
Male participants will receive a copy of the signed consent
form; a copy will be filed in the Investigator Site File and a
copy will be attached to the letter to the male participant’s
keyworker at the substance use treatment service. This let-
ter will inform the keyworker that their client has
screened positive for past year IPA and identify areas of
risk (e.g. threat/use of a weapon against partner or chok-
ing/strangulation of partner) for potential further assess-
ment by the keyworker. It will also include the name of
their client’s current and/or former female partner. Key-
workers then are able to consider the suitability of their
client to participate in the trial (e.g. cognitive deficit or
mental health problems that may limit their ability to
participate).
If eligible, following screening and their keyworkers deem
the participant suitable to take part, male participants will
complete a baseline assessment administered by the re-
searcher (see Section 3.14). The researcher will again explain
the study to eligible men, provide them with an information
sheet and get their informed consent to participate in the
trial prior to administering the baseline questionnaire. In
addition, men will complete a consent quiz [37] to ensure
they understand the trial procedures. Researchers will clarify
any incorrect responses with the participant. Men will be
randomised to treatment conditions following baseline as-
sessment. Their keyworkers will be informed of which group
they have been allocated to by a letter from the researcher.
All interviews with men will be conducted in a private room
of the substance use treatment service.
Following baseline assessment and randomisation of
male participants, their current or former female partners
will be contacted by telephone by an integrated safety ser-
vice worker to (1) inform them their current or former
partner is participating in the trial; (2) to offer them sup-
port for IPA victimisation; and (3) invite them to partici-
pate in the research by providing outcome data. Women
can accept the offer of support without participating in the
research and vice-versa. If women are interested in partici-
pating in the research, their contact details will be passed
to the research team, who will contact them within 1 week
and arrange a time for an initial interview to be conducted
with the researcher (see Section 3.14). At this meeting, the
researcher will explain the trial to the woman and gain in-
formed consent prior to administering the baseline inter-
view. Women will be interviewed in a women’s support
service, a substance use treatment service, a children’s
centre, or in exceptional cases, it may be possible for two
researchers to interview the women in her home.
After each interview, male and female participants will
be given contacts for local and national helplines and
services. If specific risk issues are identified within the
baseline assessment, appropriate steps will be taken to
manage this risk, including disclosure to the participant’s
keyworker (for male participants), and/or to the inte-
grated safety worker (for women participants).
Follow-up
Male and female participants will be followed-up at the
end of the intervention (approximately 4 months post-
randomisation) (Table 2). Reminder telephone calls or
texts will be sent in advance to arrange and confirm a
time for follow-up interview.
Method of randomisation
Male participants will be allocated to the intervention
group+ substance use treatment as usual (TAU) or TAU
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only (ratio 1:1) by site via an independent online system
based at the Clinical Trials Unit. Allocation will be at
the level of the individual participant, using randomly
varying block sizes, stratified by a combination of sites
and cycles (18 participants per site/cycle stratum).
Blinding
The statisticians will be blind to the trial condition
throughout the feasibility trial. The health economists will
not be blind to the allocation as the intervention costs will
have to be assigned to the correct treatment arm.
Fig. 1 Flow of participants through the trial
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Researchers will not be blind to the group allocation of
participants, as they will also be responsible for participant
recruitment and reminder telephone calls to attend inter-
vention sessions.
Intervention arm
The TIDieR (Template for Intervention Description and
Replication) Checklist was used to describe the interven-
tion [38] (Additional file 1: Table S3). The Behaviour
Change Wheel, incorporating the COM-B model (capabil-
ity, opportunity, and motivation for behavioural interven-
tions) was used to provide a framework to develop the
ADVANCE intervention [39]. The ADVANCE interven-
tion is voluntary, i.e. men are not mandated to attend by
the court. Within the COM-B model, the intervention
thus considered how capability, opportunity, and motiv-
ation for each could be addressed and which type of inter-
vention would be best to enact each. Thus, modelling,
enablement, education, incentivisation, and training are in-
cluded in the intervention. In the ADVANCE intervention,
capability is enhanced by increasing participants’ knowledge
and skills based on the self-regulation model. In particular,
awareness around crisis planning and self-management is
raised and automatic thoughts and beliefs are challenged by
evaluating the consequences. Opportunity is provided to
model and promote positive behaviour within intervention
sessions, and out-of-session tasks to generalise learning.
Each week, sessions were reviewed to reinforce positive
achievements. Finally, goal planning is used to motivate
participants and reinforcement of motivation is achieved
through ongoing personal support and incentives. The AD-
VANCE intervention is manualised comprising 2–4 indi-
vidual sessions (2 need to be completed before beginning
the group intervention) with a keyworker to set goals, de-
velop a personal safety plan, and increase motivation and
readiness followed by a 12-week group intervention (Fig. 2)
(Gilchrist E, Johnson A, Stephens-Lewis D, Kirkpatrick S,
McMurran M, Gilchrist G: Designing an implementation
intervention with the Behaviour Change Wheel for Men in
Substance Use Services who have been abusive to an intim-
ate female partner, in preparation). Given the high level of
trauma, family disruption, abuse, and neglect in this popu-
lation, interventions targeting IPA in men who use sub-
stances require a trauma-informed approach [40]. Recent
approaches with forensic populations indicate that
strengths-based approaches, designed for a range of learn-
ing styles, avoiding shame and judgement are more effective
[41, 42]. Three potential targets for effective IPA change
were identified as reducing pro-abuse attitudes including
locating causality for abuse in substance use, managing
Table 2 Schedule of enrolment, interventions, and assessments
Study phase
Timepoint Screening Baseline and randomisation Intervention delivery Follow-up
Enrolment:
Informed consent X X
Eligibility screen X
Baseline interview X
Allocation X
Follow-up interview X
Interventions: (16 weeks)
Intervention + TAU
TAU
Assessments:
Childhood X
Substance use X (males only) X X
Mental health X X
Intimate partner abuse X (males only) X X
Quality of life X X
Service use X X
Desirable responding X (males only) X (males only)
Motivation to change behaviour X (males only)
Self-management X (males only) X (males only)
Therapeutic alliance X (males in intervention arm only)
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distress individually and pro-socially, and learning effective,
non-abusive behavioural responses within relationship ne-
gotiations. The ADVANCE intervention focuses on devel-
oping participants’ strengths and developing healthy, non-
abusing relationships. Two main models to enable change
were selected (1) personal goal setting, to work with indi-
vidual goals, and to build genuine motivation through
alignment with personal values and facilitate change by
breaking larger longer-term aims into specific small steps
that can be more easily achieved, reinforcing motivation
through these small achievements and (2) informed by the
self-regulation model which suggests that building self-
management in one domain enables more effective self-
management across other domains. The intervention re-
quires individuals to set specific goals for reducing risk,
such as changing substance use, and for developing a pro-
social lifestyle in terms of work, leisure, health, and accom-
modation. Underpinning the goal-focused approach is the
need to improve self-regulation of behaviours, achieved by
identifying and changing cues, appraisals (thoughts), emo-
tions, behaviours, and consequences. Throughout the AD-
VANCE intervention, behaviour change skills are
introduced and practised. The 12 group sessions will ad-
dress the following:
 Session 1. Introduction to the group
 Session 2. Managing myself
 Session 3. Behaviour analysis + gender
 Session 4. Impact of intimate partner abuse
 Session 5. Children, parenting, substance use +
intimate partner abuse
 Session 6. Relating
 Session 7. Improving communication
 Session 8. Dealing with distress
 Session 9. Planning to be better
 Session 10. Positive relationships
 Session 11. New futures, peoples plans + positive
activities
 Session 12. Recap what we have learned
Pre-group individual sessions will be delivered by key-
workers in substance use treatment service. The group
intervention will also be delivered in substance use treat-
ment services by two trained facilitators, where possible
one female and one male. Keyworkers or facilitators will
check-in by phone with participants between group
sessions to address any issues arising during the session.
Participants will be given out of session practice exer-
cises. Facilitators will send a weekly feedback to partici-
pants’ keyworkers by email after each session to update
them on progress, safeguarding issues and risk. Group
sessions will be video recorded with participants’ con-
sent and checked for fidelity. Only those consenting to
being video recorded would be able to take part in the
trial.
Fortnightly, integrity support meetings will be held
with facilitators to discuss delivery issues and address
any expected problems for delivery of the next two
sessions. Four case management meetings will take place
with facilitators (and keyworkers where possible) and the
integrated safety service workers over the course of the
intervention to consider risk. Aftercare is provided in
the form of workbooks for men, keyworker guidance,
and signposting.
Contingency management, recommended by the
National Institute for Health and Care Excellence [43],
will be used to encourage motivation and retention of
participants in the group intervention by offering incen-
tives to attend the ADVANCE integrated intervention.
Participants in the intervention arm only will receive a
£5 voucher (for a shop or service of their choosing) for
attending each of the 12 sessions up to a total of £60.
These will be awarded at session 6 and session 12 of the
group intervention. If a participant attends all 12
sessions an additional £10 ‘bonus’ voucher will be avail-
able. Travel will also be reimbursed, and refreshments
provided.
The integrated safety service will also contact the
female current or former partners of males in the
Fig. 2 ADVANCE intervention
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intervention arm on at least three occasions to update
them on their current or ex-partner’s overall progress
within the intervention. They will also contact women if
there is anything that they need to know to keep them-
selves and their families safe.
Control arm
Men in both treatment arms will receive substance use
TAU including group work, individual sessions, mutual
aid, and opiate substitution treatment. Integrated safety
services and individualised support are offered to all
participants’ female current or ex-partners as needed,
regardless of the allocation to a group of their male
partners.
Data from naturalistic studies found that the relative
risk for IPA after substance use treatment was 2–3 times
greater amongst those who relapsed compared to those
who successfully completed treatment [44], potentially
as a result of a reduction in alcohol use and improved
relationship functioning. Therefore, the selection of
substance use TAU as a comparator for this feasibility
study is justified. Moreover, men’s keyworkers will be in-
formed that their client has perpetrated IPA in the past
12 months regardless of group allocation and may
choose to address this as part of TAU.
Fidelity
All group intervention sessions will be video recorded
with participants’ and facilitators’ consent. Facilitators’
fidelity of the delivery of the intervention manual will be
assessed by a trained observer using a pre-defined check-
list for each session of the intervention. Video recordings
will allow the same observer to assess treatment integ-
rity, the degree to which treatment is implemented as
intended across sites. Sessions are videotaped for
assessment of treatment fidelity, therapist skill, and com-
petency in delivering the interventions and the discrim-
inability of the study treatments. Treatment fidelity will
be assessed using an adapted form of the Yale School of
Medicine Adherence and Competence Scale [37], shown
to be successful at discriminating key therapy content
and skill domains [38]. A series of checklists are created
to tap into key unique components of specific therapies
(e.g. experimental condition vs. control) as well as a
series of scales tapping common factors (e.g. assessment
of substance use and general functioning).
Formative evaluation
At the end of each group session, men will be asked to
self-complete a brief evaluation form. Facilitators will
complete a brief treatment adherence form after each
session. All TAU contacts will be recorded by keywor-
kers for men (regardless of treatment arm). Integrated
safety support workers will record contacts with the
current or ex female partners of men in both treatment
arms. Focus groups with staff at the end of each cycle of
the intervention will examine their experiences of deliv-
ering the intervention. After completion of the first cycle
of the intervention at each site, interviews with partici-
pants will explore their experiences and acceptability of
attending the intervention and participating in the trial.
Feasibility measures
The primary objective of this study is to demonstrate
the feasibility of conducting a trial to evaluate the inter-
vention, including the feasibility and acceptability of
delivering the intervention in substance use treatment
and the feasibility of outcome measure collection on
perpetrators and their current or former female partners.
The following feasibility parameters will be examined:
rates of consent, recruitment, and follow-up by site and
group allocation. The estimation of background variabil-
ity will inform sample size calculations for a future
evaluation trial.
Men’s TAU attendance for both treatment arms,
attendance, and retention in the ADVANCE interven-
tion for men allocated to the treatment arm, and
numbers of current or former female partners accepting
the offer of support from the integrated safety service
will also be collected.
Participant-centred outcome measures
The suitability and acceptability of outcome measures
will be assessed to determine the feasibility of including
them in a future effectiveness trial. Researchers’ percep-
tions of participants’ understanding (e.g. of language and
meaning of questions) and acceptability (e.g. if partici-
pant refuses to answer or gets annoyed/frustrated or
asks to end the interview) will be recorded for each out-
come measure using a pre-determined rating scale (1—
lowest rating to 3—highest rating for understanding and
acceptability). The following outcome measures will be
assessed at baseline for men and initial interview for
women and at the end of the intervention (4 months
post-randomisation of men) for men in both treatment
arms and their current or former female partners (unless
otherwise specified) (Table 2).
Substance use
The Alcohol Use Disorders Identification Test (AUDIT)
(included in the baseline questionnaire only) is a 10-item
screening tool used to assess alcohol use in the past 12
months [45]. Scores range from 0 to 40. Total scores of
8 or more for men (7 or more for women) indicate
hazardous and harmful alcohol use, and scores of 20 or
above indicate alcohol dependence.
The Drug Use Disorders Identification Test (DUDIT)
(included in the baseline questionnaire only) is an 11-
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item screening tool used to identify drug-related prob-
lems [46]. Scores range from 0 to 44. Total scores of 6
or more for men (2 or more for women) indicate drug-
related problems, and scores of 25 or more indicate drug
dependence.
As the AUDIT and DUDIT assess substance use in the
past 12 months they will not be used to measure
substance use outcomes post-intervention (4 months
post-randomisation). Instead, the average amount on a
using day and number of days substances used in each
of the past 4 weeks will be recorded using the Treatment
Outcome Profile [47] at baseline and follow-up. The
number of days in the past 4 weeks that problems with
particular substances were experienced will also be
recorded using The Addiction Severity Index [48] as will
current treatment for substance use.
Mental health
The Patient Health Questionnaire (PHQ-9) is a 9-item
scale measuring depressive symptoms in the past 2
weeks [49]. The total score ranges from 0 to 27. A score
≥ 10 has a sensitivity of 88% and a specificity of 88% for
major depression.
The Generalised Anxiety Disorder Assessment (GAD-7)
is a 7-item scale measuring general anxiety symptoms in
the past 2 weeks [50]. The total score ranges from 0 to
21. A score of ≥ 10 represents a reasonable cut off point
for identifying cases of GAD.
The Primary Care Post-Traumatic Stress Disorder
(PTSD) Screen (PC-PTSD-5) is a 5-itccem screen for
PTSD in the past month, with scores ranging from 0 to
5 [51]. A score of ≥ 3 indicates PTSD.
The Standardised Assessment of Personality—Abbrevi-
ated Scale (SAPAS) (included in male baseline question-
naire only) is an 8-item screening interview for
personality disorder [52] enquiring about a person’s be-
haviour in general rather than a specific time frame.
Scores range from 0 to 8. A score ≥ 3 correctly identified
the presence of DSM-IV personality disorder in 90% of
participants.
Intimate partner abuse (victimisation and perpetration) in
the past 4 months
The Abusive Behaviour Inventory Revised (ABI-R) is a
25-item reliable tool to measure experiences of physical
(13 items), psychological (9 items), and sexual abuse (3
items) victimisation and perpetration [36]. Each item
can be scored from 1 (never) to 5 (very frequently). The
higher the score on each subscale, the greater the
frequency of abuse.
Controlling behaviours in relation to both perpetration
and victimisation will be assessed using four adapted
questions from the 24 item Revised Controlling Behav-
iours Scale (CBS-R) [53]: smash your partner’s property
when annoyed/angry; want to know where your partner
went and who they spoke to when not together; tell your
partner they were going mad; and try to restrict time
your partner spent with family or friends. Total score for
the 4 questions ranges from 0 to 16; the higher the
score, the greater the frequency of a partner using
controlling behaviours.
The Communications Patterns Questionnaire-Short
Form (CPQ-SF) [54] is an 11-item self-assessment of
“spouses’ perceptions of marital interactions … to indi-
cate the representativeness of that description for the
conflict and communication patterns in their relation-
ship”: male demand/female withdraw; female demand/
male withdraw; original total demand/withdraw; alter-
nate demand/withdraw; criticise/defend and positive
interaction. Higher scores on each subscale suggest
which communication pattern is likely to be used during
conflict interactions.
Two scales (9 items) from The Intimate Partner
Violence Responsibility Attribution Scale (IPVRAS)
(included in the male baseline and follow-up question-
naires only) will assess perpetrators’ responsibility attribu-
tion to the victim (V) and responsibility attribution to the
offender’s (i.e. perpetrator’s) personal context (O) [55].
The higher the score, the more responsibility attributed to
the victim (V) or offender’s personal context (O).
The 12-item anger subscale from The Propensity for
Abusiveness Scale (PAS) (included in the male baseline
and follow-up questionnaires only) is included. The PAS
predicts the perpetration of physical and emotional
abuse. Scores on the anger subscale range from 12
(completely undescriptive of you) to 60 (completely
descriptive of you) [56].
Two questions from a non-validated scale on the use
of social media in relation to perpetration and victimisa-
tion of a partner will be included [57] (e.g. ‘Used mobile
technology to check her location’). Total scores range
from 2 (never) to 10 (very frequently); the higher the
score, the greater the frequency of abuse using social
media.
Four questions will be used from a non-validated scale
to assess the use of children against a partner [35] (e.g.
“Asked the children to report on what your current or
former partner is doing or where she has been”). Total
scores range from 4 (never) to 20 (very frequently); the
higher the score, the greater the frequency of using
children against a partner/the greater the frequency of
having a partner use children against you.
There will be a question on the frequency of stop-
ping a partner from leaving the house against their
will/being stopped from leaving the house will be
scored from 1 (never) to 5 (very frequently). Two
questions on stalking behaviours scoring from 2
(never) to 5 (very frequently); the higher the score,
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the greater the frequency of experiencing or perpet-
rating stalking behaviour.
Self-management
The 13-item Brief Self-Control Scale (BSCS) enquires
about typical dispositional self-regulatory behaviours using
two factors of self-control: restraint and impulsivity [58]
(included in the male baseline and follow-up question-
naires only). Total scores range from 13 (not at all like
me) to 65 (very much like me).
Quality of life
The ICEpop CAPability measure for Adults (ICECAP-A)
is used to assess a person’s well-being using a capability
approach [59]. It has five attributes: attachment (an
ability to have love, friendship, and support); stability
(an ability to feel settled and secure); achievement (an
ability to achieve and progress in life); enjoyment (an
ability to experience enjoyment and pleasure), and
autonomy (an ability to be independent), each with four
levels of capacity. Tariff values range from 1 (full
capability) to 0 (no capability).
The EQ-5D-3L consists of a descriptive system and a
Visual Analogue Scale (VAS). The descriptive system
assesses five dimensions of a person’s health state
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) on the day of administering, each
with three response levels: no problems, some problems,
and extreme problems [60]. The tariff index score based
on the descriptive profile ranges from 1 (perfect health)
to – 0.594 (worst health), with death anchored at 0 for
the UK valuation set [61]. The EQ VAS records the
respondent’s current self-rated health on a vertical visual
analogue scale from 0 (worst imaginable health) to 100
(best imaginable health).
Healthcare, social, and other legal and civil services use
and criminal justice contacts
Participants’ utilisation of primary and secondary health-
care, social services, and other legal and civil services,
including the prescribing of medication, and their con-
tacts with criminal justice will be recorded retrospect-
ively by self-report questionnaire.
Experience of the group intervention (males allocated to
the intervention arm, follow-up questionnaire only)
The 12-item Working Alliance Inventory–Short Revised
(WAI-SR) client version measures three key aspects of
therapeutic alliance: agreement on the tasks of therapy,
agreement on therapy goals, and affective bond develop-
ment [62]. Scores range from 5 to 60, with higher scores
indicating a better therapeutic alliance between client
and therapist. The patient version of the California Psy-
chotherapy Alliance Scale- Short Form [63] has 12 items
that measures the alliance in psychotherapy across 4
subscales: the patient working capacity, patient commit-
ment, working strategy consensus, and therapist under-
standing and involvement. The total score is the mean
of these four subscales.
The following will also be assessed and may be used as
explanatory variables.
Socio-demographic information
Data on participants’ relationship status, age, gender,
ethnicity, highest education level attained, living arrange-
ments, current employment status, number of children,
and their living arrangements will be recorded.
Childhood
The occurrence of ten Adverse Childhood Experiences
(ACE) (e.g. physical, sexual, emotional abuse, neglect,
household dysfunction) experienced before the age of 18
were assessed to produce an ACE score of cumulative
childhood stress [64] (assessed in baseline questionnaire
only). Scores range from 0 to 10; the higher the score
the greater the childhood adversity experienced.
Desirable responding
The Balanced Inventory of Desirable Responding Short
Form (BIDR-SF) [65] (administered to male participants
only). The BIDR-SF consists of two subscales: Self-
Deceptive Enhancement (honest but overly positive
responding) and Impression Management (bias toward
pleasing others or ‘deliberate self-presentation’). Higher
scores indicating more desirable responses. IPA scores
will be adjusted for BIDR-SF scores.
Motivation to change behaviour
The URICA-Domestic Violence (URICA-DV), adminis-
tered to male participants only, is a 32-item measuring
perpetrators’ readiness to end their violence [66].
URICA-DV includes four subscales to measure stages of
change pre-contemplation, contemplation, action, and
relapse. Responses are given on a 5-point Likert scale
ranging from 1 (strong disagreement) to 5 (strong
agreement).
Database systems
A web based electronic Case Report Forms system
(InferMed MACRO) will be used to collect baseline and
outcome data. The system is Good Clinical Practice
compliant with full audit trail and database lock func-
tionality and a range of validations will be programmed
to minimise data entry errors. No data analysis will be
undertaken until databases are locked.
Ten percent of coded questionnaires and 10% of
entered data by site will be verified by the trial manager
to check for errors. If coded questionnaires and data
Gilchrist et al. Pilot and Feasibility Studies            (2020) 6:62 Page 12 of 16
entered are found to contain errors, a further 10% will
be checked.
Ethical issues
The trial will be conducted in compliance with the prin-
ciples of the Declaration of Helsinki [67], the principles
of Good Clinical Practice, and all of the applicable regu-
latory requirements (UK data protection laws (meaning
the Data Protection Act 1998 until 24 May 2018, and
from 25 May 2018 the European Union General Data
Protection Regulation (GDPR) and applicable UK legisla-
tion that enshrines GDPR into UK law).
As part of the informed consent process, participants
will be advised and provided guidance about confidenti-
ality and the limits to it. Significant risk of future harm
to self or others will be disclosed to their keyworker or
the duty worker in the substance use service or the inte-
grated safety service where the interview is taking place,
or to the relevant authorities.
The trial may be prematurely discontinued by the
Sponsor or Chief Investigator on the basis of new safety
information or for other reasons given by the Data Mon-
itoring and Ethics Committee/Trial Steering Committee,
regulatory authority or ethics committee concerned. The
trial may also be prematurely discontinued due to lack
of recruitment or upon advice from the Trial Steering
Committee. If the study is prematurely discontinued,
active participants will be informed and no further
participant data will be collected.
All serious adverse events resulting from participation
in the trial will be reported to the Ethics Committee
within 48 h of receiving the report.
Research reimbursement
Male and female participants will be reimbursed in cash
or vouchers for their time for completing baseline or
follow-up interviews (£10) and taking part in focus
groups or qualitative interviews (£20). All research
participants will receive £5 travel expenses for attending
a research interview.
Sample size calculation
The sample size for a feasibility study should allow
parameters required to inform the design of the defini-
tive randomised controlled trial to be estimated. To esti-
mate a standard deviation for a sample size calculation
of a future evaluation trial, a sample of at least 50 partic-
ipants is recommended [68]. Therefore, to recruit a
sample size of 60 female current or former partners (i.e.
30 whose current or ex male partners in the intervention
arm and 30 whose partners are in the control arm), and
taking a conservative retention rate of 80% of female
current or former partners at end of intervention assess-
ment (4 months post-randomisation), we will recruit 76
female current or former partners. It is estimated that
around 70% of current or former female partners will
agree to take part in the trial, therefore approximately
108 male participants will need to be recruited to obtain
a sample of 76 female current or former partners.
Statistical analysis
This feasibility trial will estimate parameters needed for
planning an efficacy trial including estimating various
rates (e.g. recruitment, randomisation, follow-rates) and
estimating the within-trial arm standard deviation, the
pre-post correlation, and the Intracluster Correlation
Coefficient (ICC) for possible outcome measures to
inform the sample size calculation of a future rando-
mised control trial. Outcome measures will be rated by
the researcher for each participant for their suitability
and acceptability and the mean scores summarised for
each outcome. Outcome measures will be described by
trial arm. Intervention effect sizes (e.g. incidence rate
ratios for the count outcome and mean differences for
continuous outcome measures) will be estimated for
various outcome measures, but no formal hypotheses
testing will be carried out.
Economic analysis
The costs of providing the intervention will be collected
from local data sources to estimate the incremental cost
of delivering the ADVANCE intervention over and
above substance use TAU. Questionnaires on the use of
primary and secondary health and social care services
and contacts with criminal justice services by men (and
their female current or ex-partners) in the intervention
and control groups will record quantities of resource
use. This resource use will be multiplied by unit costs to
estimate a cost profile for each participant. The returned
questionnaires will be analysed to assess the acceptability
of data collection methods, identify barriers to data col-
lection and highlight the most commonly used services
in this population. A more appropriate questionnaire for
an efficacy trial can be developed based on the feasibility
trial data. A cost profile will be estimated for each
participant, including trial-related costs and wider
service use costs and presented by treatment arm.
Qualitative analysis
Focus groups and semi-structured interviews will be
digitally recorded and transcribed verbatim. Data will be
organised and coded using NVivo. Multiple coders will
enhance the rigour of the analysis. Framework analysis
will be used for qualitative data analysis using five steps:
familiarization; identifying a thematic framework; index-
ing; charting; and mapping and interpretation [69].
Collecting multiple perspectives data (e.g. from male and
female participants, keyworkers, intervention facilitators,
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and women’s support staff) in a qualitative formative
evaluation will provide a better understanding of the
intervention’s implementation. The framework approach
allows the exploration of patterns in themes across
different participants and groups of participants.
Data management
In accordance with the Trial Terms of Reference, the
Data Monitoring and Ethics Committee will periodically
review overall safety data to determine patterns and
trends of events, or to identify safety issues, which would
not be apparent on an individual case basis and report
their findings to the Trial Steering Committee who will
provide overall supervision of the feasibility trial.
Data handling and storage
Participants’ contact details will be stored on a secure
password protected server for 3–6 months after the
study has ended. Consent forms will be stored at each
site in a locked cabinet and will not contain the partici-
pant identification number. Paper copies of question-
naires will be stored separately from the consent forms
and contain only a participant identification number. A
unique identification code will be assigned to electronic
sound files and transcripts of the focus groups, known
only to appropriate members of the research team. Any
personal information required will also be coded with
this identification number and kept in a password
protected server. Audio files will not contain partici-
pant’s names and will not be stored on the recording
device. Audio files will be downloaded onto a secure ser-
ver. As soon as the audio file is checked on the server, it
will be deleted from the recording device. Any quotes
published will be anonymous further protecting partici-
pant confidentiality. Recordings will be archived in a
secure location for a minimum period of 7 years.
Discussion
IPA remains a leading contributor to disease burden
[70]. It is estimated that the annual cost of domestic
abuse in England and Wales is over £66 billion, mainly
due to the cost of physical and emotional harms experi-
enced by victims/survivors (£47 billion) [71]. There is a
need to find effective interventions to reduce IPA
perpetration, especially amongst high-risk groups such
as substance users. Current provision of community
perpetrator groups does not meet demand nor is it
tailored to the specific needs of men in substance use
treatment. This unmet need led to the development of
the ADVANCE intervention. It is hoped that delivering
tailored IPA interventions in substance use treatment
will increase their ability to reach men who may not
otherwise be referred to perpetrator interventions and
result in better outcomes for male perpetrators and
improved wellbeing for their female partners.
This feasibility trial, and nested formative evaluation,
will inform the design of a future trial to evaluate the
clinical efficacy and cost-effectiveness trial.
Trial status
The trial sponsor is South London and Maudsley NHS
Foundation Trust. The screening began on 5 July 2018,
with the first male participant randomised on 17 July
2018. Recruitment will end on 7 May 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00580-7.
Additional file 1: Table S3. The TIDieR (Template for Intervention
Description and Replication) Checklist. Information to include when
describing an intervention and the location of the information.
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